Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReSPECT Study of rezafungin prophylaxis after allogeneic blood and marrow transplantation
2017-004981-85Phase 3Active
- Sponsor
- Cidara Therapeutics
- Start
- Dec 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rezafungin in invasive mycoses and mycoses (2 arms), sponsored by Cidara Therapeutics. Primary endpoint: Fungal-free survival at Day 90. Started Dec 2019; status: active.
02
Drugs
rezafungin
03
Conditions
invasive mycosesmycoses
Beyond the preview
Go deeper on 2017-004981-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004981-85.